CP-102

**CP-102** is CardioPharma's investigational fixed-dose cardiovascular polypill comprising **atorvastatin, lisinopril, and aspirin**. The combination is intended to address cardiovascular disease through complementary mechanisms: atorvastatin competitively inhibits HMG-CoA reductase to reduce cholesterol synthesis; lisinopril inhibits angiotensin-converting enzyme to reduce angiotensin II formation and blood pressure; and aspirin irreversibly inhibits platelet cyclooxygenase to suppress thromboxane-mediated platelet aggregation. CardioPharma lists CP-102 as a pipeline line extension based on generic cardiovascular medicines, with no clinical phase or approved marketing status publicly specified. ([cardiopharma.com](https://www.cardiopharma.com/cardiapill-pipeline/))

Other names

atorvastatin + lisinopril + aspirinatorvastatin-lisinopril-ASA